# IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

> **NCT04086264** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 218 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** IMGN632
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT04086264
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-11-06
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04086264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04086264, "IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04086264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*